IL7RA polymorphisms predict the CD4+ recovery in HIV patients on cART
María Guzmán-Fulgencio
Unidad de Infección Viral e Inmunidad, Centro Nacional de Microbiología, Instituto de Salud Carlos III, Majadahonda, Madrid, Spain
Search for more papers by this authorJuan Berenguer
Unidad de Enfermedades Infecciosas/VIH, Hospital General Universitario ‘Gregorio Marañón’, Madrid, Spain
Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Madrid, Spain
Search for more papers by this authorMaría Angeles Jiménez-Sousa
Unidad de Infección Viral e Inmunidad, Centro Nacional de Microbiología, Instituto de Salud Carlos III, Majadahonda, Madrid, Spain
Search for more papers by this authorDariela Micheloud
Servicio de Medicina Interna, Hospital General Universitario ‘Gregorio Marañón’, Madrid, Spain
Search for more papers by this authorMónica García–Álvarez
Unidad de Infección Viral e Inmunidad, Centro Nacional de Microbiología, Instituto de Salud Carlos III, Majadahonda, Madrid, Spain
Search for more papers by this authorJosé María Bellón
Fundación para la investigación Biomédica del Hospital General Universitario ‘Gregorio Marañón’, Madrid, Spain
Search for more papers by this authorTeresa Aldámiz-Echevarría
Unidad de Enfermedades Infecciosas/VIH, Hospital General Universitario ‘Gregorio Marañón’, Madrid, Spain
Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Madrid, Spain
Search for more papers by this authorPilar García-Broncano
Unidad de Infección Viral e Inmunidad, Centro Nacional de Microbiología, Instituto de Salud Carlos III, Majadahonda, Madrid, Spain
Search for more papers by this authorPilar Catalán
Servicio de Microbiología, Hospital General Universitario ‘Gregorio Marañón’, Madrid, Spain
Search for more papers by this authorCristina Diez
Unidad de Enfermedades Infecciosas/VIH, Hospital General Universitario ‘Gregorio Marañón’, Madrid, Spain
Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Madrid, Spain
Search for more papers by this authorDaniel Pineda-Tenor
Unidad de Infección Viral e Inmunidad, Centro Nacional de Microbiología, Instituto de Salud Carlos III, Majadahonda, Madrid, Spain
Search for more papers by this authorCorresponding Author
Salvador Resino
Unidad de Infección Viral e Inmunidad, Centro Nacional de Microbiología, Instituto de Salud Carlos III, Majadahonda, Madrid, Spain
Correspondence to: Salvador Resino, Centro Nacional de Microbiología, Instituto de Salud Carlos III (Campus Majadahonda), Carretera Majadahonda- Pozuelo, Km 2.2; 28220 Majadahonda (Madrid), Spain. Tel.: +34 918 223 266; fax: +34 918 223 269; e-mail: [email protected]Search for more papers by this authorMaría Guzmán-Fulgencio
Unidad de Infección Viral e Inmunidad, Centro Nacional de Microbiología, Instituto de Salud Carlos III, Majadahonda, Madrid, Spain
Search for more papers by this authorJuan Berenguer
Unidad de Enfermedades Infecciosas/VIH, Hospital General Universitario ‘Gregorio Marañón’, Madrid, Spain
Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Madrid, Spain
Search for more papers by this authorMaría Angeles Jiménez-Sousa
Unidad de Infección Viral e Inmunidad, Centro Nacional de Microbiología, Instituto de Salud Carlos III, Majadahonda, Madrid, Spain
Search for more papers by this authorDariela Micheloud
Servicio de Medicina Interna, Hospital General Universitario ‘Gregorio Marañón’, Madrid, Spain
Search for more papers by this authorMónica García–Álvarez
Unidad de Infección Viral e Inmunidad, Centro Nacional de Microbiología, Instituto de Salud Carlos III, Majadahonda, Madrid, Spain
Search for more papers by this authorJosé María Bellón
Fundación para la investigación Biomédica del Hospital General Universitario ‘Gregorio Marañón’, Madrid, Spain
Search for more papers by this authorTeresa Aldámiz-Echevarría
Unidad de Enfermedades Infecciosas/VIH, Hospital General Universitario ‘Gregorio Marañón’, Madrid, Spain
Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Madrid, Spain
Search for more papers by this authorPilar García-Broncano
Unidad de Infección Viral e Inmunidad, Centro Nacional de Microbiología, Instituto de Salud Carlos III, Majadahonda, Madrid, Spain
Search for more papers by this authorPilar Catalán
Servicio de Microbiología, Hospital General Universitario ‘Gregorio Marañón’, Madrid, Spain
Search for more papers by this authorCristina Diez
Unidad de Enfermedades Infecciosas/VIH, Hospital General Universitario ‘Gregorio Marañón’, Madrid, Spain
Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Madrid, Spain
Search for more papers by this authorDaniel Pineda-Tenor
Unidad de Infección Viral e Inmunidad, Centro Nacional de Microbiología, Instituto de Salud Carlos III, Majadahonda, Madrid, Spain
Search for more papers by this authorCorresponding Author
Salvador Resino
Unidad de Infección Viral e Inmunidad, Centro Nacional de Microbiología, Instituto de Salud Carlos III, Majadahonda, Madrid, Spain
Correspondence to: Salvador Resino, Centro Nacional de Microbiología, Instituto de Salud Carlos III (Campus Majadahonda), Carretera Majadahonda- Pozuelo, Km 2.2; 28220 Majadahonda (Madrid), Spain. Tel.: +34 918 223 266; fax: +34 918 223 269; e-mail: [email protected]Search for more papers by this authorAbstract
Background
The IL7RA polymorphisms have recently been associated with CD4+ T-cell decline in untreated HIV-infected subjects and CD4+ T-cell recovery in patients on combination antiretroviral therapy (cART). The aim of this study was to evaluate whether IL7RA polymorphisms are associated with CD4+ T-cell recovery in HIV-infected patients on long-term cART.
Study design
We performed a retrospective study in 151 naïve cART patients with severe immunodeficiency (CD4+ counts ≤200 cells/mm3). IL7RA polymorphisms' genotyping was performed using Sequenom's MassARRAY platform. The outcome variable was the time to achieve the first value of CD4+ count ≥500 cells/mm3 during the follow-up.
Results
Two different trends of CD4+ T-cell recovery were found in Kaplan–Meier analysis. During the first 48 months, 60 of 151 (39·7%) of the patients reached CD4+ T-cell values ≥500 cells/mm3, and no differences were observed between IL7RA genotypes. After the first 48 months of follow-up, 27 of 151 (17·8%) of the patients reached CD4+ T-cell values ≥500 cells/mm3, with a different pattern of CD4+ recovery depending on IL7RA genotype. Patients with rs10491434 TT genotype and rs6897932 TT genotype were more likely of achieving CD4+ value ≥500 cells/mm3 than patients with rs10491434 CT/CC genotype (adjusted hazard ratio (aHR) = 3·59; P = 0·005) and patients with rs6897932 CC/CT genotype (aHR = 11·7; P < 0·001).
Conclusions
The IL7RA polymorphisms seem to be associated with CD4+ T-cell recovery in HIV-infected patients who started cART with severe immunodeficiency, in the second phase of CD4+ T-cell recovery after long-term cART.
References
- 1Saag MS, Holodniy M, Kuritzkes DR, O'Brien WA, Coombs R, Poscher ME et al. HIV viral load markers in clinical practice. Nat Med 1996; 2: 625–9.
- 2O'Brien WA, Hartigan PM, Martin D, Esinhart J, Hill A, Benoit S et al. Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS. Veterans Affairs Cooperative Study Group on AIDS. N Engl J Med 1996; 334: 426–31.
- 3Kaplan JE, Benson C, Holmes KH, Brooks JT, Pau A, Masur H. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep 2009; 58: 1–207; quiz CE201-204.
- 4Lozano F, Pedrol P, Polo R, Aguirrebengoa K, Berenguer J, Pedrol P, et al. National consensus document by GESIDA/National Aids Plan on antiretroviral treatment in adults infected by the human immunodeficiency virus (January 2011 update). Enferm Infecc Microbiol Clin 2011; 29: 209 e1–103.
- 5Thompson MA, Aberg JA, Hoy JF, Telenti A, Benson C, Cahn P et al. Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA 2012; 308: 387–402.
- 6Gutierrez F, Padilla S, Masia M, Iribarren JA, Moreno S, Viciana P et al. Clinical outcome of HIV-infected patients with sustained virologic response to antiretroviral therapy: long-term follow-up of a multicenter cohort. PLoS ONE 2006; 1: e89.
- 7Kelley CF, Kitchen CM, Hunt PW, Rodriguez B, Hecht FM, Kitahata M et al. Incomplete peripheral CD4+ cell count restoration in HIV-infected patients receiving long-term antiretroviral treatment. Clin Infect Dis 2009; 48: 787–94.
- 8Helleberg M, Kronborg G, Larsen CS, Pedersen G, Pedersen C, Obel N et al. Poor CD4 response despite viral suppression is associated with increased non-AIDS-related mortality among HIV patients and their parents. AIDS 2013; 27: 1021–6.
- 9Baker JV, Peng G, Rapkin J, Krason D, Reilly C, Cavert WP et al. Poor initial CD4+ recovery with antiretroviral therapy prolongs immune depletion and increases risk for AIDS and non-AIDS diseases. J Acquir Immune Defic Syndr 2008; 48: 541–6.
- 10Guzman-Fulgencio M, Berenguer J, Micheloud D, Fernandez-Rodriguez A, Garcia-Alvarez M, Jimenez-Sousa MA et al. European mitochondrial haplogroups are associated with CD4+ T cell recovery in HIV-infected patients on combination antiretroviral therapy. J Antimicrob Chemother 2013; 68: 2349–57.
- 11Massanella M, Negredo E, Clotet B, Blanco J. Immunodiscordant responses to HAART–mechanisms and consequences. Expert Rev Clin Immunol 2013; 9: 1135–49.
- 12Corbeau P, Reynes J. Immune reconstitution under antiretroviral therapy: the new challenge in HIV-1 infection. Blood 2011; 117: 5582–90.
- 13Capitini CM, Chisti AA, Mackall CL. Modulating T-cell homeostasis with IL-7: preclinical and clinical studies. J Intern Med 2009; 266: 141–53.
- 14Limou S, Melica G, Coulonges C, Lelievre JD, Do H, McGinn S et al. Identification of IL7RA risk alleles for rapid progression during HIV-1 infection: a comprehensive study in the GRIV cohort. Curr HIV Res 2012; 10: 143–50.
- 15Hartling HJ, Thorner LW, Erikstrup C, Harritshoj LH, Kronborg G, Pedersen C et al. Polymorphism in interleukin-7 receptor alpha gene is associated with faster CD4(+) T-cell recovery after initiation of combination antiretroviral therapy. AIDS 2014; 28: 1739–48.
- 16Rajasuriar R, Booth D, Solomon A, Chua K, Spelman T, Gouillou M et al. Biological determinants of immune reconstitution in HIV-infected patients receiving antiretroviral therapy: the role of interleukin 7 and interleukin 7 receptor alpha and microbial translocation. J Infect Dis 2010; 202: 1254–64.
- 17Hutchinson JN, Raj T, Fagerness J, Stahl E, Viloria FT, Gimelbrant A et al. Allele-specific methylation occurs at genetic variants associated with complex disease. PLoS ONE 2014; 9: e98464.
- 18Bewick V, Cheek L, Ball J. Statistics review 12: survival analysis. Crit Care 2004; 8: 389–94.
- 19Gregory SG, Schmidt S, Seth P, Oksenberg JR, Hart J, Prokop A et al. Interleukin 7 receptor alpha chain (IL7R) shows allelic and functional association with multiple sclerosis. Nat Genet 2007; 39: 1083–91.
- 20Kreft KL, Verbraak E, Wierenga-Wolf AF, van Meurs M, Oostra BA, Laman JD et al. Decreased systemic IL-7 and soluble IL-7Ralpha in multiple sclerosis patients. Genes Immun 2012; 13: 587–92.
- 21Rajasuriar R, Booth DR, Gouillou M, Spelman T, James I, Solomon A et al. The role of SNPs in the alpha-chain of the IL-7R gene in CD4+ T-cell recovery in HIV-infected African patients receiving suppressive cART. Genes Immun 2012; 13: 83–93.
- 22Crawley AM, Faucher S, Angel JB. Soluble IL-7R alpha (sCD127) inhibits IL-7 activity and is increased in HIV infection. J Immunol 2010; 184: 4679–87.
- 23Hodge JN, Srinivasula S, Hu Z, Read SW, Porter BO, Kim I et al. Decreases in IL-7 levels during antiretroviral treatment of HIV infection suggest a primary mechanism of receptor-mediated clearance. Blood 2011; 118: 3244–53.
- 24Spaulding A, Rutherford GW, Siegfried N. Tenofovir or zidovudine in three-drug combination therapy with one nucleoside reverse transcriptase inhibitor and one non-nucleoside reverse transcriptase inhibitor for initial treatment of HIV infection in antiretroviral-naive individuals. Cochrane Database Syst Rev 2010; 10: CD008740.
- 25Negredo E, Molto J, Burger D, Viciana P, Ribera E, Paredes R et al. Unexpected CD4 cell count decline in patients receiving didanosine and tenofovir-based regimens despite undetectable viral load. AIDS 2004; 18: 459–63.
- 26Motta D, Brianese N, Foca E, Nasta P, Maggiolo F, Fabbiani M et al. Virological effectiveness and CD4+ T-cell increase over early and late courses in HIV infected patients on antiretroviral therapy: focus on HCV and anchor class received. AIDS Res Ther 2012; 9: 18.
- 27Potter M, Odueyungbo A, Yang H, Saeed S, Klein MB. Impact of hepatitis C viral replication on CD4+ T-lymphocyte progression in HIV-HCV coinfection before and after antiretroviral therapy. AIDS 2010; 24: 1857–65.
- 28McGovern BH, Golan Y, Lopez M, Pratt D, Lawton A, Moore G et al. The impact of cirrhosis on CD4+ T cell counts in HIV-seronegative patients. Clin Infect Dis 2007; 44: 431–7.
